82520-37-4

Basic information

• Product Name: 3-METHOXY-4'-METHYLBENZOPHENONE
• Synonyms: 3-METHOXY-4'-METHYLBENZOPHENONE;(3-METHOXYPHENYL)(4-METHYLPHENYL)METHANONE;OTAVA-BB 1044025
• CAS NO: 82520-37-4
• Molecular Formula: C₁₅H₁₄O₂
• Molecular Weight: 226.27
• Product Categories: Aromatics
• Mol File: 82520-37-4.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 145-150°C at 0.6 mm Hg
• Flash Point: 169.8°C
• Appearance: /
• Density: 1.088g/cm³
• Vapor Pressure: 8.06E-06mmHg at 25°C
• Refractive Index: 1.563
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: 3-METHOXY-4'-METHYLBENZOPHENONE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXY-4'-METHYLBENZOPHENONE(82520-37-4)
• EPA Substance Registry System: 3-METHOXY-4'-METHYLBENZOPHENONE(82520-37-4)

Safety Data

• Hazardous Substances Data: 82520-37-4(Hazardous Substances Data)

Usage

Chemical Properties

Viscus Yellow Oil

Uses

3-Methoxy-4’-methylbenzophenone (cas# 82520-37-4) is a compound useful in organic synthesis.

Preparation

Complex preparation: Tandem catalysis access to ketones from aldehydes and –arylboronic acids via rhodium-catalyzed addition/oxidation.

InChI:InChI=1/C15H14O2/c1-11-6-8-12(9-7-11)15(16)13-4-3-5-14(10-13)17-2/h3-10H,1-2H3

Upstream product

• 1711-05-3 m-anisoyl chloride 
• 108-88-3 toluene 
• 5142-75-6 tri(p-tolyl)bismuth 
• 10365-98-7 3-methoxyphenylboronic acid 
• 104-87-0 4-methyl-benzaldehyde 
• 201230-82-2 carbon monoxide 
• 106-38-7 para-bromotoluene 
• 624-31-7 4-tolyl iodide 
• 42498-32-8 N-tert-butyl-4-methylbenzamide 
• 36282-40-3 (3-methoxyphenyl)magnesium bromide 
• 49834-28-8 N-(tert-butyl)-3-methoxybenzamide 
• 4294-57-9 para-methylphenylmagnesium bromide 
• 586-38-9 3-Methoxybenzoic acid 
• 66117-64-4 di(p-tolyl)borinic acid 

Downstream Products

• 1312552-03-6 4-[(10-allyl-9,10-diazatricyclo[4.2.1.1(2,5)]dec-9-yl)-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide 
• 1312552-02-5 4-[(10-allyl-9,10-diazatricyclo[4.2.1.1(2,5)]dec-9-yl)-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide 
• 1312555-08-0 4-[(9,10-diazatricyclo[4.2.1.1(2,5)]dec-9-yl)-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide 
• 1312554-93-0 4-[(10-benzyl-9,10-diazatricyclo[4.2.1.1(2,5)]dec-9-yl)-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide 
• 150428-54-9 BWB 373 
• 156727-75-2 SNC 79 
• 156727-71-8 SNC 67 
• 156727-74-1 (+)-4-[(αR)-α-(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl-3-methoxybenzyl]-N,N-diethylbenzamide 
• 156727-72-9 SNC 83 
• 150428-54-9 SNC 88 
• 150428-54-9 SNC 89 
• 155836-50-3 4-((alpha-R)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N-diethylbenzamide 
• 150428-54-9 SNC 85 
• 186094-10-0 4-[Chloro-(3-methoxy-phenyl)-methyl]-N,N-diethyl-benzamide 

Relevant articles and documents

Kumada Arylation of Secondary Amides Enabled by Chromium Catalysis for Unsymmetric Ketone Synthesis under Mild Conditions

The synthesis of aromatic ketones by chromium-catalyzed Kumada arylation of secondary amides with organomagnesium reagents is described. This reaction was enabled by using low-cost chromium(III) salt as a precatalyst, combined with trimethylsilyl chloride

PHARMACEUTICAL COMPOUNDS

Diazapolycyclic compounds having affinity for the opioidergic receptors, preferably for the delta opioidergic receptors, with central and/or peripheral activity, having formula: [in-line-formulae]A1-D1-T1??(I)[/in-line-formulae] wherein: A1 is a group of formula (II): wherein: R1 is phenyl wherein one of the ring hydrogen atoms is substituted with a group selected from C(O)R′, C(O)OR′, C(O)NHR′ or C(O)NR3R4, R′, R3 and R4, being as defined in the application; R2 is phenyl, optionally substituted D1 is a diazapolycyclic group T1 is a group selected from H, alkyl, alkenyl, alkynyl and from the following optionally substituted groups: cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, arylalkyl or heteroarylalkyl, and their hydrates and solvates and pharmaceutically acceptable salts.

SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.